Ocumension Therapeutics
0.54
EUR
-0.01
(-2.70%)
ISIN
KYG674111011
CUSIP
G67411101
Return %
Stock
S&P 500
1Y
-32.92
14.20
3Y
-39.33
81.12
5Y
-73.00
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Ye Liu
- Full Time Employees
- 552
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- No. 1858 Yinzhongnan Road Suzhou JS China
- IPO Date
- Jul 10, 2020
- Website
- ocumension.com
- Similar Companies
- Business
- Ocumension Therapeutics Ocumension Therapeutics (1477.HK) is a China-based ophthalmic pharmaceutical platform company principally engaged in the discovery, development, manufacturing and commercialization of first- or best-in-class therapies for ophthalmic diseases. Founded in 2017 and headquartered in Suzhou, China, the company operates primarily in the People's Republic of China with select rights extending to Greater China, Southeast Asia and global markets for certain products; it maintains a robust pipeline of 25 pharmaceutical assets covering front- and back-of-the-eye conditions including glaucoma, ocular hypertension, allergic conjunctivitis, dry eye, bacterial conjunctivitis, myopia, uveitis and choroidal neovascularization. Its core commercialized products include OT-401 (YUTIQ, fluocinolone acetonide intravitreal implant for posterior segment uveitis), OT-1005 (Azep, azelastine hydrochloride eye drops for allergic conjunctivitis), OT-204 (Ou Qin, sodium hyaluronate eye drops for dry eye), OT-303 (brimonidine tartrate eye drops for glaucoma and ocular hypertension), OT-402 (Visudyne, verteporfin for choroidal neovascularization), OT-601 (moxifloxacin eye drops for bacterial conjunctivitis), OT-1001 (Zerviate, cetirizine hydrochloride eye drops for allergic conjunctivitis in Greater China and Southeast Asia), as well as generics such as latanoprost (Shilida) and timolol maleate (Emadine) eye drops for glaucoma; pipeline assets encompass OT-502 (DEXYCU), OT-301 (NCX 470, NO-donating prostaglandin analog for glaucoma), OT-101 and OT-101-S (low-concentration atropine for myopia) and OT-702 (anti-VEGF). In August 2024, Ocumension Therapeutics entered a strategic agreement with Alcon Inc. to acquire outright ownership in China of Tears Natural Forte, Bion Tears, Alcaine, Fluorescite and Cyclogyl procedural drops, alongside commercialization rights for Systane Ultra dry eye drops and AR-15512 (a novel topical dry eye candidate), issuing 139,161,120 shares to Alcon representing 16.71% of its enlarged share capital post-transaction, thereby enhancing its dry eye portfolio, assuming local manufacturing responsibilities after a transition period and establishing mutual rights of first negotiation for future products. The company employs 505 people and holds a minority stake in EyePoint Pharmaceuticals Inc., positioning it as a leader in China's ophthalmology sector with multiple phase III trials and registration-stage drugs.